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Abstract The effect of subcutaneous (SC) peginterferon
b-1a exposure on reduction of gadolinium-enhanced (Gd?)
lesion count over time was evaluated in patients with
relapsing-remitting multiple sclerosis (RRMS) in a Phase 3
study (ADVANCE). Patients were randomized to receive
SC injections of placebo (n = 500), 125 mcg every-2-
weeks (n = 512), or 125 mcg every-4-weeks (n = 500) for
1 year, and then active treatment in the second year. Steady
state 4-week AUC (AUCss) was derived for each individ-
ual based on sparse pharmacokinetic (PK) sample and a
population PK model. Several longitudinal count models,
including marginal, mixed effect, and mixture models,
were compared to explore the relationship between AUCss
and Gd? lesion count (or T2 lesion count). A mixture
model which divided subjects into two subpopulations by
low and high baseline lesion activity was found to yield
best goodness-of-fit for the data. In this model, the point
estimate and 95 % CI for drug effect slope on log(k) are
-0.0256 (-0.0304, -0.0216) for Gd? lesion and -0.0147
(-0.0170, -0.0124) for T2 lesion. This suggested that
reduction of Gd? lesion (or T2 lesion) count over time is
significantly related to SC peginterferon b-1a exposure,
and that the increased reduction lesion count with the
every-2-week regimen versus the every-4-week regimen
was driven by the higher exposure achieved in that
treatment arm (mean Gd? lesion count 0.2 and 0.7 at Year
2, respectively). The every-2-week regimen produced an
exposure range that was close to the plateau range of the
exposure–response curve, supporting its selection as the
regulatory approved dosage.
Keywords Peginterferon b-1a  Multiple sclerosis 
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Introduction
Multiple sclerosis (MS) is a chronic disease of the central
nervous system. It is predominantly a disease of young
adults, primarily women, with disease onset typically
occurring between the ages of 20 and 40. MS primarily
affects myelinated fiber tracts. Histologically, it is char-
acterized by focal areas of demyelination, astrogliosis, the
relative preservation of axons, and varying degrees of
inflammation [1].
Peginterferon b-1a, a PEGylated form of interferon b-1a
(IFN b-1a), has been approved for the treatment of
relapsing multiple sclerosis (RMS). Treatment with IFN b-
1a 30 mcg intramuscular (IM) injection weekly has proven
to be effective in delaying the progression of disability and
in reducing the rate of clinical relapses in MS. Peginter-
feron b-1a has a longer half-life and greater exposure
compared to IFN b-1a; therefore, with a reduced admin-
istration frequency, it potentially reduces side effects (e.g.
flu-like symptoms) while increasing convenience and
improving treatment compliance [2, 3].
In the ADVANCE study, a pivotal Phase 3 study, after
1 year of treatment, SC peginterferon b-1a every-2-weeks
reduced annualized relapse rate (ARR; primary endpoint)
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by 36 %. Risk of relapse, risk of disability progression, and
the number of new or newly enlarging T2 lesions (sec-
ondary endpoints), together with gadolinium-enhanced
(Gd?) lesions (tertiary endpoint), were also reduced when
compared with placebo. The safety profile reflected that of
established IFN b-1a therapies [4]. The 2-year results
showed that peginterferon b-1a efficacy was maintained
beyond 1 year, with greater effects observed with every-2-
week versus every-4-week dosing, and a similar safety
profile to Year 1 results [5].
Gd? lesions (also called enhancing lesions), T2-hyper-
intense lesions, and T1-hypointense lesions (T1 black
holes) are the basis for the three classic measures of MS
pathology visible by conventional magnetic resonance
imaging (MRI), and are the cornerstone of MRI-based
outcomes in MS clinical trials [6]. Gadolinium (Gd) che-
lates are widely used as contrast agents in MRIs of the
brain and spinal cord. Data from animal studies and from
MS brain biopsy studies have demonstrated that Gd
enhancement is associated with histopathological evidence
of blood–brain barrier breakdown and inflammation.
Studies indicate that enhancement occurs in almost all the
new lesions from patients with relapsing-remitting or sec-
ondary progressive MS. Generally speaking, the enhance-
ment of a new lesion lasts 2–3 weeks in most cases [7, 8].
T2-hyperintense lesions (T2 lesions) provide a comple-
mentary set of measures to enhancing lesions in both
clinical trials (counts or volumetrics) and in clinic (prin-
cipally counts). New T2 lesion counts in most circum-
stances are strongly correlated with enhancing lesion
counts in high-frequency serial studies. While enhancing
lesions provide a measure of inflammation only around the
time of the MRI, new T2 lesions represent a measure of
disease activity over the interval.
The objectives of the current analyses were to explore
and evaluate the relationship between the population phar-
macokinetic (PK) exposure predicted for peginterferon b-1a
and the observed Gd? lesion count over time in the
ADVANCE study. Similar analyses were performed for T2
lesion count, except that instead of assuming the mean count
of new or newly enlarged lesions declined over time, it was
assumed to be proportional to duration of observation. To
avoid redundancy, this paper will focus on the method and
results for the analysis of Gd? lesion count, and the mod-
eling outcome for T2 lesion count will be briefly mentioned.
Methods
Study design and patients
ADVANCE was a 2-year, Phase 3, multicenter, random-
ized, double-blind, parallel-group study with a 1-year,
placebo-controlled period. The full methods from the
ADVANCE study have been published previously [4, 5].
During Year 1 of the study, patients were randomized
(1:1:1) to receive SC injections of placebo (n = 500),
peginterferon b-1a at a dose of 125 mcg every-2-weeks
(n = 512), or peginterferon b-1a at a dose of 125 mcg
every-4-weeks (n = 500). At the end of Year 1, patients on
placebo were re-randomized to either peginterferon b-1a
125 mcg every 2 or 4 weeks, while patients on peginter-
feron b-1a during Year 1 continued their treatment. During
the first year of the study, 44, 62, and 74 subjects dropped
out of the study in the placebo, every-4-weeks and every-2-
weeks arms, respectively. Among the subjects who con-
tinued into the Year 2 portion of the study, 75 and 59
subjects dropped out of the study in the every-4-weeks and
every-2-weeks arms, respectively. Key eligibility criteria
were a diagnosis of RRMS as defined by the McDonald
criteria, age 18–65 years, a score of between 0 and 5 on the
expanded disability status scale (EDSS; with higher scores
indicating greater disability [9]), and at least two clinically
documented relapses in the previous 3 years, with at least
one of these relapses having occurred within the 12 months
prior to randomization. Patients who had progressive forms
of MS, pre-specified laboratory abnormalities, and prior
interferon treatment for MS exceeding 4 weeks or dis-
continuation less than 6 months prior to baseline were
excluded. The protocol was approved by each site’s insti-
tutional review board and was conducted according to the
International Conference on Harmonization Guidelines for
Good Clinical Practice and the Declaration of Helsinki.
Every patient provided written informed consent prior to
study entry [4, 5].
Pharmacodynamic (PD) measurements
MRI scans for detection of Gd? lesions and T2 lesions
were conducted at baseline, Week 24, Week 48, and Week
96. The number of Gd? lesions was recorded for each
individual at these visits. The number of new or newly
enlarging T2 hyperintense lesions was recorded at Week
24, Week 48, and Week 96.
Population PK modeling
The population PK analysis was carried out using a non-
linear mixed-effect model approach with NONMEM soft-
ware (ICON plc, Dublin, Ireland, version 7.2). The final PK
parameter estimates used in this analysis were based on
nonparametric bootstrapping results using the final popu-
lation PK model developed elsewhere [10]. One thousand
data sets were generated by repeatedly sampling with
replacement stratified by intensive and sparse sampling
type from the Phase 3 ADVANCE study PK data set. The
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median values of these bootstrapped parameters were used
as model population parameters, and post hoc PK param-
eters for all subjects were obtained by setting MAX-
EVAL = 0 in NONMEM.
Modeling of longitudinal count data
Analysis of longitudinal Gd? lesion count data is abundant
in the literature. Albert et al. [11] described Gd? lesion
count data collected at monthly intervals for approximately
30 months with two types of models: a Poisson time series
in which the mean changes as a function of sinusoidal trend
and past observations, and a Poisson time series with the
mean fluctuating according to a hidden Markov chain.
Altman et al. [12] extended the hidden Markov model in
[11], and also proposed a more efficient algorithm for
model parameter estimation. Both [11] and [12] focused on
the within-subject change of mean lesion count over time,
and the models were fitted to data at individual level.
Recognizing the interpatient heterogeneity in disease
activity, MacKay Altman et al. [13] further extended the
hidden Markov model to a mixed hidden Markov model
and the model was fit to data from a group of patients
simultaneously. While not analyzing lesion count data,
Troco´niz et al. [14] compared Poisson, zero-inflated Pois-
son (ZIP), negative binomial, and zero-inflated negative
binomial model for daily seizure count data, which dis-
played a common feature with the Gd? lesion count data:
overdispersion and Markovian properties. Velez de Men-
dizabal et al. [15] also compared several discrete distri-
bution models for monthly Gd? lesion count over
48 months in nine MS patients; these models incorporated
different distribution families (Poisson, ZIP, generalized
Poisson, negative binomial, and zero-inflated negative
binomial) with or without Markovian element.
With this analysis, we established the relationship
between the change in mean lesion count over time and the
peginterferon b-1a exposure. In addition, other than
exploring the models described in the literature, we
extended the models used in the literature by introducing a
two-population mixture model to describe the interpatient
heterogeneity observed in the ADVANCE study.
Exposure–response modeling
Spagatti plot by individual (as in Fig. 1 for Gd? lesion
count) suggested that the distribution of lesion count is
similar across different visits when patients were on pla-
cebo. This was also confirmed by comparison of empirical
cumulative distribution function curves and summary
statistics (data shown). These analyses suggested that dis-
ease activity for both type of lesions are stable with
1 year placebo treatment; therefore, it was assumed that
underlying distribution for lesion count did not change
when subjects were on placebo treatment.
The half-life of peginterferon b-1a was previously
reported to be *78 h in RRMS patients with no accumu-
lation in either the every-2-week or every-4-week treat-
ment regimens [16]. Since change in the Gd? lesion
formation process is gradual, it was deemed unlikely that
the Gd? lesion count would change in response to change
in instantaneous peginterferon b-1a concentration. A more
likely indirect response model, while potentially suit-
able for describing the underlying relationship, was not
appropriate given the limited number of lesion count
observations available per individual. As a result, we
estimated individual AUCss as the exposure parameter and
the temporal pattern for drug effect onset was described by
an empirical first-order exponential function as suggested
by the data. The AUCss was derived according to Eq. (1)
where DOSE equals 125 mcg, N represents the total
number of doses received over 4 weeks (N = 2 for sub-
jects in the every-2-week group; N = 1 for subjects in the
every-4-week group), and CL represents post hoc clearance
estimate for each subject:
AUCss ¼ DOSE  N
CL
ð1Þ
We also explored Poisson distribution and negative
binomial distribution for our response data.
In order to account for the excess zeros observed in the
data set, the ZIP distribution was also tested. The ZIP
distribution is defined as in Eq. (2):
P x ¼ kð Þ ¼
P0 þ 1 P0ð Þ  exp kð Þ; if k ¼ 0
1 P0ð Þ  k
k
k!





where x is the random variable for lesion count, k is an
observed outcome, P0 is the inflated proportion of zero
counts, and k is the mean parameter. This model assumes
that the observations of lesion count are coming from two
processes: one process for the excess zeros and the other
process that behaves as a regular Poisson. The Negative
Binomial distribution allows a flexible relationship
between mean and variance. Its probability mass function
is given in Eq. (3):


















where x is the random variable for lesion count, k is an
observed outcome, k is the mean parameter, and OVDP is a
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parameter reflecting over-dispersion. Similarly, the Nega-
tive Binomial distribution can be modified to accommodate
an excess proportion of zeros.
Emax and log-linear function forms were explored to
describe the effect of AUCss on Gd? lesion count:




kij ¼ ki0  exp b AUCij
  ð5Þ
In Eqs. (4) and (5), kij is the mean parameter of dis-
tribution for subject i at time j (days since first dose of
active dose), ki0 is the baseline k, AUCij is the AUCss
value for subject i at time j (it is either 0 for subjects on
placebo treatment or at baseline, or the estimated steady
state level, if at time j the subject was on peginterferon b-
1a treatment). In the Emax model, parameter Emax rep-
resents the maximal proportional change in baseline k,
and EC50 stands for the AUCss at which 50 % of the
maximum reduction can be achieved. In the log-linear
model, parameter b is the slope of AUCss effect in log
scale.
In the case of a zero-inflated distribution, the drug effect
can not only influence parameters k, but also parameter P0,





¼ P0 þ c AUCij; ð6Þ
In Eq. (6), P0,ij stands for the inflated proportion of 0
lesion count at time j for subject i, P0 is the inflated pro-
portion of 0 count at baseline or when receiving placebo
treatment, and c is the slope parameter for drug effect.
Marginal (naı¨ve pooled) model and mixed-effect model
were tested initially. With the mixed-effect model, random
effect on baseline ki0 was assumed to follow a log-normal
distribution. Given the observed large proportion of sub-
jects with zero lesion count during the entire study, a
mixture model was further tested. With the mixture model,
random effect on baseline ki0 was assumed to come from
two sub-populations: a sub-population with low lesion
activity and a sub-population with relatively higher lesion
activity (Eq. (7)). Two different over-dispersion parame-
ters, OVDP1 and OVDP2, were used for the two sub-
groups. Since each individual only contributed one AUCss
value, random effects on slope parameter were considered
non-identifiable and therefore were not included.
ki0 ¼ ki0;1  I Y ¼ 1f g þ ki0;2  I Y ¼ 0f g ð7Þ
where Y Bernoullið1; hÞ, ki0;1 LogNormalðl1;x21Þ, ki0;2
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Fig. 1 Observed Gd? lesion count over time for each individual were
overlaid and grouped by initial treatment assignment. Each line
represents one subject. The data displayed large between-subject as
well as within-subject variation. In addition, the shift of distribution of
lesion count toward zero is apparent after treatment with SC
peginterferon b-1a, and is more pronounced with the every-2-week arm
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Preliminary visual inspection suggested peginterferon
b-1a treatment gradually decreases Gd? lesion count over
time and the maximum effect was observed at Week 54 or
beyond; therefore, a first-order exponential function was
adopted to describe the time course of drug effect onset,
which is described in Eq. (8) for the log-linear model case.
In Eq. (8), tij is the day after first dose of active dose
(would be 0 at baseline or for placebo treatment) and t1/2 is
the pharmacologic half-life effect parameter to be esti-
mated. The term is a multiplicative factor added on the
exposure effect; therefore, as tij increases, the value of this
term goes to 1 and maximum drug effect (or steady state
effect) is achieved.




 !" # !
ð8Þ
The same models were applied to the longitudinal new
or newly enlarged T2 lesion count data, except that instead
of assuming a first-order exponential decline for the onset
of drug effect, the mean lesion count observed in each time
interval is assumed to be proportional to the length of the
observation interval.
Model evaluation
To evaluate the goodness-of-fit for the model, the marginal
proportion of each observed outcome is compared to either
population-predicted marginal probabilities or the average
of individual predicted probabilities.
An alternative approach of model evaluation was a
simulation-based visual predictive check (VPC). Five
hundred data sets were simulated using the final model and
corresponding parameter estimates. The data were first
binned according to the value of AUCss. Data were divided
into 21 subgroups: one subgroup for zero AUC and another
20 subgroups for positive AUC such that an approximately
equal number of subjects are in each subgroup. Within
each bin, for any pre-specified grouping of outcomes (e.g.
lesion count = 0, lesion count = 1, 2 B lesion count B 4,
and lesion count[ 4), the observed marginal proportion
was overlaid with the corresponding 90 % prediction
interval based on simulation. In addition, to evaluate
whether the variability described by the model reflects the
variability in observed data, the mean and variance of
lesion count in each bin in each simulated data set were
obtained and compared to that of the observed data.
Finally, a non-parametric bootstrap was used to evaluate
the uncertainty of the model parameter estimation [17].
One thousand bootstrap data sets were generated; each
contained the same number of subjects as the original data
set and they were randomly drawn with replacement. For
each of the 1000 bootstrap data sets, the model parameters
were estimated. The mean and the 95 % confidence inter-
val (CI) for all the parameters based on the bootstrap
replicates were compared to the estimates from the original
data set.
Statistical analysis software
Data sets for Gd? lesion count were assembled using SAS
(SAS Institute Inc., Cary, NC, USA, version 9.3). Both
estimation of individual AUCss and the PK/PD analysis
were carried out in NONMEM (ICON plc, Dublin, Ireland,
version 7.2). Laplacian approximation method was used for
parameter estimation. VPC and bootstrap procedure were
implemented with PsN version 4.4.0. [18, 19]) and plotted
with Xpose 4.5.3 [20, 21]. Data plotting was implemented
with R software (R Foundation for Statistical Computing,
Vienna, Austria, version 3.1.1).
Results
Patient demographics
A full description of participant flow in the ADVANCE
study, and details of baseline demographic and clinical
characteristics in each treatment group, have been pub-
lished previously [4]. The population enrolled in this study
was consistent with a general multiple sclerosis population.
A total of 1505 subjects were included in this analysis
(497, 510, and 498 subjects enrolled to placebo, peginter-
feron b-1a 125 mcg every-2-weeks, and peginterferon b-1a
125 mcg every-4-weeks at baseline, respectively).
Gd1 lesion count
At Year 2, relative to the peginterferon b-1a every-4-week
group, the number of Gd? lesions was reduced by 71 %
(p\ 0.0001) in the peginterferon b-1a every-2-weeks
group (0.2 and 0.7 for the every-2-week and every-4-week
respectively). Individual Gd? lesion counts across visits
are displayed in Fig. 1 by treatment assignment for the
2 year period. The data revealed large between-subject as
well as within-subject variation. In addition, the shift in the
distribution of lesion count toward zero is apparent after
treatment with peginterferon b-1a, and it is more pro-
nounced within the every-2-week arm.
Another characteristic of this data set is the high pro-
portion of zero count. Across the three treatment arms, 38,
57, and 43 % of subjects had no Gd? lesions over all four
MRI scans in the placebo, the every-2-week, and the every-
4-week arms, respectively. At the same time, there was a
small proportion of lesion counts that were C30 in each
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arm. This indicated that the distribution of lesion counts is
heavily skewed toward zero; however, there is also a heavy
tail toward the large counts. As a result, high over-dis-
persion is a feature of the data (in Supplementary Fig. S2,
marginal mean of Gd? lesion count was plotted against the
variance of Gd? lesion count for subgroups defined by
AUCss, which suggested high over-dispersion).
Model comparison
A comparison of the different models tested in the analysis
of Gd? lesion counts is summarized in Table 1.
With the marginal Poisson model (Model 1, Table 1),
the minimum objective function value (OFV) was 23,223.8
and the estimated slope parameter for exposure effect was
-0.0254. As shown in Fig. 3, this model did a poor job
predicting the probability of either small counts (0, 1, 2,
and 3) or large counts (C10).
The marginal ZIP model (Model 2, Table 1) was then
fitted to the data, where a parameter to reflect extra pro-
portion of zeros was added to a regular Poisson distribution
(parameter P0 in Eq. (2)). The OFV for this model was
16,840.5, which corresponded to a reduction of 6383.3
points compared to the marginal Poisson model. The
parameter P0 is estimated to be 0.596. As the effect of
peginterferon b-1a exposure is parameterized to both
reduce the mean of regular Poisson component (parameter
k in Eq. (2)) as well as increase the extra proportion of zero
(parameter P0 in Eq. (2)), two drug effect parameters were
required and their estimates were -0.0116 and 0.0163,
respectively.
The marginal negative binomial model (Model 3,
Table 1) yielded an OFV of 11,960.8, which was a further
reduction of 4879.7 from the marginal ZIP model. The
estimated drug effect slope was -0.0209. The estimated
OVDP parameter was 13.4, indicating the variability of
data is much larger than the mean of data. Figure 3a, b
suggested a much improved fit in both ends of the distri-
bution curve, although slight over-estimation for the
probability of zero count was apparent. However, the
marginal zero-inflated negative binomial model appeared
to be over-parameterized, and it failed to converge.
The marginal models assume that all the subjects share a
common baseline level of k. However, in-depth review of
the individual profiles revealed that, although within-sub-
ject variability across different visits could be large, in
general, subjects with more active disease tend to have
more lesions observed in multiple visits, or in the contrast,
consistently low lesion counts were observed across mul-
tiple visits. This is an indication that different subjects have
different inherent disease activity levels. Therefore, adding
a random effect into the model to account for between-
subject variability in baseline disease activity would be a
natural next step to explore. As it was apparent from prior
tested models that negative binomial models are more
suitable for such over-dispersed data, only negative bino-
mial models were further evaluated.
In the mixed effect negative binomial model (Model 4,
Table 1), the individual baseline mean count ki0, which
reflects underlying Gd? lesion disease activity prior to
treatment with peginterferon b-1a, was assumed to follow a
log-normal distribution. The model also converged suc-
cessfully and all parameters were estimated with relative
standard error (RSE) less than 19 %. The OFV for this
model was 11,310.1, reflecting a reduction of 650.7 from
the marginal negative binomial model. The estimated drug
effect slope was -0.0267. The omega parameter (variance
for gk) was estimated to be 1.712, which translated into a
coefficient of variation of 131 % in the between-subject
variation in baseline disease activity. Interestingly, the
OVDP parameter estimation was reduced to 0.788; this
suggests that, once the large between-subject variation in
the baseline disease activity was accounted for, the vari-
ability of observations at individual level was much
Table 1 Comparison of different models tested for Gd? lesion count
Model Description OFV Estimated slope of
AUC effect
Model 1 Naı¨ve pooled poisson model 23,223.8 -0.0254
Model 2 Naı¨ve pooled zero-inflated Poisson model, log-linear model for AUC effect on k, and logistic
model for AUC effect on P0
16,840.5 -0.0116 on k
0.0163 on P0
Model 3 Naı¨ve pooled negative binomial model, time effect was removed to allow convergence 11,960.8 -0.0209
Model 4 Mixed effect negative binomial model, random effect on baseline rate parameter ki0 (assuming
log-normal distribution), over-dispersion parameter OVDP assumed constant
11,310.1 -0.0267
Model 5 Mixture model on baseline rate parameter ki0 with two log-normally distributed sub-populations,
OVDP assumed to be different for each sub-population
10,971.4 -0.0256
In all models, the AUC effect on mean Gd? lesion count was assumed to follow a log-linear model, and drug-effect onset was described by a
first-order exponential function
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reduced. This is in contrast to the large value of estimated
OVDP parameter in the marginal negative model, where it
groups together both the between- and within-subject
variation. A further evaluation of the distribution of
Empirical Bayesian Estimates of gk indicates that its dis-
tribution is highly skewed and substantially deviated from
normal distribution (Fig. 2); many subjects had small
yet almost identical values of estimated gk. This indicates
that the log-normal distribution is not appropriate for the
random effect of baseline mean Gd? lesion count.
The final model was a mixture negative binomial model
(Model 5, Table 1) with two subpopulations for the
between-subject variation on baseline mean parameter ki0,
which reflects that 40–60 % of the subjects had no recor-
ded Gd? lesions across all four MRI scans. Again, the
model converged successfully and the OFV was 10,971.4.
Although visually the improvement on the marginal prob-
ability in Fig. 3a, b is quite subtle, there appears to be
better fitting, especially in the tail part of the distribution
curve, with the mixture negative binomial model. The
parameter estimates, together with the RSEs, are given in
Table 2. The median as well as the 95 % CI based on the
bootstrap for each parameter are listed in Table 2, con-
firming that all parameters were estimated with good
precision.
The model suggests that approximately 60 % of the
subjects fall into the lower baseline lesion activity sub-
population (see also Supplementary Fig. S1). The typical
values of ki0 are estimated to be 0.48 and 1.69 for the lower
baseline lesion activity and higher baseline lesion activity
sub-populations, respectively. This was a sizeable separa-
tion between these two groups. The model estimated the
between-subject variability on ki0 for the lower baseline
lesion activity group to be very small; therefore, it was set
to zero. The between-subject random effect on ki0 for the
higher lesion activity sub-population was estimated to have
a 112 % coefficient of variation, which implied large
heterogeneity in disease activity among patients. Different
OVDP parameters were needed for the two sub-populations
and they were estimated to be 44.8 and 0.5 for the low
lesion activity and high lesion activity groups, respectively.
At first inspection, this appeared to be counter-intuitive.
However, since the OVDP value for the lower lesion
activity group encompasses both between- and within-
subject variation and mean lesion count was smaller in this
group, the ratio between variance and mean was indeed
large.
The estimated slope of AUCss effect on log(k) is
-0.0256; this implied that, with each additional increase of
27 ng/mL h in AUCss, k was reduced by an additional
50 %. Across the every-2-week AUCss range, the range of
decline was much narrower than that across the every-4-
week AUCss range; in addition, the mean decline for the
every-2-week group was greater than that of the every-4-
week group.
Figure 4 displays the observed proportion of different
lesion counts (0, 1, 2, 3, 4, 5, 6, 7, and[7 counts) in each
AUCss bin, with the corresponding 95 % CI based on 1000
simulation runs. The clear trend of increased proportion of
zero count with increasing AUCss, or decreased proportion
of one or more lesion counts with increasing AUCss, gen-
erally lies inside the confidence band. This is also true for
large count numbers and the observed proportions fall well
within the 95 % CI. In addition, the observed variance and
mean for each subgroup defined by AUCss were similar to
those from 20 simulated data sets (see also Supplementary
Fig. S3). The greater-than-proportional increase in the
variance relative to mean in the observed data was well
reflected in the simulated data sets. This implies that the
model not only captured the central tendency of the data
well, but that it also represented the variability of the data
well.
In Fig. 5, observed marginal mean Gd? lesion counts
by AUCss subgroup were overlaid with mean and 95 % CI
based on 1000 simulations. Boxplots for the population-
PK-model-estimated AUCss in every-2-week and every-4-
week arms are also shown. The simulation-based mean
curve is aligned with the central tendency of the observed
data. In addition, the observed mean lesion counts lie
within the simulation-based 95 % CI. Similar marginal
mean lesion count was observed across the range of AUCss
resulting from the every-2-week regimen. However, in the





















Fig. 2 Quantile–quantile plot for empirical Bayes estimate of gk0 in
the mixed effect negative binomial model (Model 4). The random
effect on baseline k was assumed to follow a log-normal distribution;
therefore, gk0 should follow a normal distribution. However, the lower
end of the distribution significantly deviated from the Normal
distribution. This part of the distribution comprised predominantly
subjects with no lesions observed during the trial and their g estimate
would be different only when the corresponding AUCss is different.
This graph indicates that the individual level k cannot be differen-
tiated for these subjects; therefore, grouping them into a sub-
population was performed
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substantial difference in marginal mean lesion count was
either observed in the data or predicted by the model
among the low AUC subgroup and high AUC subgroup.
T2 lesion count
Similar models were tested on the longitudinal T2 lesion
count data, and the relative performance of these models in
terms of goodness-of-fit are in the same order as for Gd?
lesion count data (model comparison was presented in
Table 3; estimates of parameters in the final model pre-
sented in Table 4). The final model selected to describe T2
lesion count data was also a mixture negative binomial
model with two sub-populations for the between-subject
variation on baseline mean parameter ki0. The effect of
AUCss on log(k) is estimated to be -0.0147, with a stan-
dard error (SE) of 0.0011. This suggested that AUCss is a
highly significant covariate on T2 lesion count and
increased AUCss led to a greater reduction of T2 lesion
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Fig. 3 Goodness-of-fit for
marginal probability of
observed count in the entire data
set across different models.
a count B10; b count[10.
Observed marginal probabilities
(diamonds) were overlaid with
model-predicted marginal
probabilities (lines) for different
models. For each unique lesion
count observed in the data set,
the marginal probability is
defined as the ratio between the
total number of the count and
the total number of observations
in the data set. To calculate the
model-predicted marginal
probability for a particular
count, the probability of
observing this count at each
visit for each individual is first
obtained based on individual
empirical Bayes estimates of
parameters and then averaged
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Median 95 % CI




R Ratio of the mean Gd? lesion count for a typical subject in higher baseline lesion activity
group to lower baseline lesion activity group
3.53 3.58 (2.58, 4.73)
l2 Baseline mean Gd? lesion count for a typical subject in the higher baseline lesion activity
sub-population
1.69 1.70
r1 Dispersion parameter for baseline k in the lower baseline lesion activity sub-population 44.8 44.7 (39.6, 50.8)
r2 Dispersion parameter for baseline k in the higher baseline lesion activity sub-population 0.499 0.496 (0.398,
0.586)
h Proportion of subjects with lower baseline lesion activity 0.602 0.602 (0.561,
0.651)
b Slope of AUC effect on log(k) -0.0256 -0.0257 (-0.0304,
-0.0216)
t1/2 Half-life of drug effect onset time (days) 115 113.8 (73.8, 179.6)
r2 Variance of random effect on baseline k in log scale for the higher baseline lesion activity
sub-population
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Fig. 4 Visual predictive check
for marginal probability of
different lesion count categories
(0, 1, 2, 3, 4, 5, 6, 7, and[7
counts) based on 1000
simulations with Model 5 the
mixture negative binomial
model. The Gd? lesion count
observations were divided into
21 groups according to
associated AUCss (one group for
zero AUCss and 20 groups for
all positive AUCss). The dots
connected by a line were the
observed proportion for
different lesion count categories
and the shaded region were the
corresponding 90 % CI based
on simulation. The dots along
the x-axis are the boundary
value of each AUC bin
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and a smaller difference in T2 lesion count was observed
among subjects receiving the every-2-week regimen com-
pared to the every-4-week regimen.
Discussion
Since Gd? lesions represent acute blood–brain barrier
disruption, the number of Gd? lesions is highly unpre-
dictable at different time points within a subject. There was
one subject in the placebo arm who had 6 Gd? lesions at
the baseline visit but 40 and 33 lesions at Week 24 and
Week 48, respectively; lesion count reduced to zero after
switching to the every-2-weeks regimen for 1 year. Nev-
ertheless, subjects with very few lesions at baseline tend to
have a small number of lesions across all scans, while
subjects with a relatively greater number of lesions at
baseline are more likely to record larger lesion counts. This
indicates that both between- and within-subject variation in
counts are high and an appropriate model should be able to
reflect these features simultaneously.
Multiple models were tested in this study, including
marginal models with regular Poisson, zero-inflated Pois-
son, regular negative binomial, zero-inflated negative
binomial, mixed effect negative binomial, and mixture
negative binomial. Not surprisingly, none of the marginal
models can adequately reflect such an irregular distribution
of count data. Both the mixed effect negative binomial
model and the mixture negative binomial model with two
sub-populations performed significantly better than the
marginal models. Judging from multiple factors, including
the precision in parameter estimation, the value of the
estimated parameter, goodness-of-fit for either marginal
probability of each observed count or variance versus mean
plot by subgroups of AUCss, or VPC on the proportion of
different counts binned by AUCss, the mixture negative
binomial model appeared to be the most robust model.
Compared to the paper by Velez de Mendizabal et al.,
the Gd? lesion count data displayed similar features,
which are high between-subject and within-subject vari-
ability, over-dispersion, and large proportion of zero count.
Their data were monthly observations from nine individ-
uals, and the data set we analysed here are much more
sparse at an individual level but have a larger sample size.
While incorporating a Markovian feature in the model
would not be supported by the data due to long interval
between MRI acquisitions, the lesion count data never-
theless indicated correlation within individuals and large
sample size allowed us to divide the subjects into two sub-
populations with different levels of lesion activity. Both
analyses found negative binomial model fits the data better
than Poisson model (even with a zero-inflated component).























Cumulative AUC Over 4 Weeks (ng/mL*hr)
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Peginterferon beta-1a every 4 weeks
Peginterferon beta-1a every 2 weeks
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95% CI for Simulated Mean
Fig. 5 Observed marginal mean Gd? lesion count by AUCss
subgroup, overlaid with mean and 95 % CI based on 1000 simula-
tions. Boxplot of the population PK model estimated AUCss in the
every-2-week and every-4-week arms. The simulation-based mean
curve is aligned with the central tendency of the observed data. In
addition, the observed mean lies within the simulation-based 95 %
CI. Across the range of AUCss resulting from the every-2-week
regimen, marginal mean Gd? lesion count had little change.
However, in the range of AUCss resulting from the every-4-week
regimen, a substantial difference in marginal mean Gd? lesion count
was either observed in the data or predicted by the model
Table 3 Comparison of different models tested for new or newly enlarged T2 lesion count
Model Description OFV Estimated slope of
AUC effect
Model 1 Naı¨ve pooled poisson model 45,024.1 -0.017
Model 2 Naı¨ve pooled zero-inflated Poisson model, log-linear model for AUC effect on k, and logistic
model for AUC effect on P0
33,561.6 -0.0117 on k
0.011 on P0
Model 3 Naı¨ve pooled negative binomial model 18,267.5 -0.0143
Model 4 Mixed effect negative binomial model, random effect on baseline rate parameter ki0 (assuming
log-normal distribution), over-dispersion parameter OVDP assumed constant
17,021.6 -0.0157
Model 5 Mixture model on baseline rate parameter ki0 with two log-normally distributed sub-populations,
OVDP assumed to be different for each sub-population
16,726.9 -0.0147
In all models, the AUC effect on mean T2 lesion count was assumed to follow a log-linear model, and mean parameter k is assumed to be
proportional to the duration of observation for which new or newly enlarged T2 lesion were recorded
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binomial model with first and second order Markov factors,
the estimated underlying mean lesion count was 0.94.
Interestingly, this number is very similar to the weighted
mean baseline lesion count for the two sub-populations
(0.96) observed in our analysis, which suggests that
reduced MRI acquisition frequency did not undermine the
estimation of underlying lesion activity. This suggests that
for a large-scale clinical study, the increased cost associ-
ated with more frequent MRI scans does not provide much
additional value in terms of estimating the treatment effect.
The estimated between-subject variability on k was 66 %
in the de Velez de Mendizabal et al. paper, and the estimate
was 112 % for the high disease activity sub-group in our
analysis, but it is foreseeable that for the entire population,
it would be smaller and closer to their estimate.
The large heterogeneity in lesion activity among the MS
patients enrolled in clinical studies is very common; similar
phenomenon have been observed in clinical studies for
several other MS treatments (data not shown). Apparently,
it is difficult to show treatment effect in subjects with low
lesion activity; therefore, for future clinical studies in MS
patients where Gd? or T2 lesion count serves as a primary
endpoint (e.g. Phase 2 dose-ranging studies), it is a plau-
sible idea to enrich patient population by selecting subjects
with at least one lesion at baseline in order to improve the
sensitivity of a study to detect drug effect.
Conclusions
We tested multiple models to describe the relationship
between longitudinally collected Gd? (and T2) lesion count
and steady state peginterferon b-1a AUC. A mixture nega-
tive binomial model with two sub-populations adequately
Table 4 Non-parametric bootstrap analysis and parameter estimates of the final model for new or newly enlarged T2 lesion count (Model 5








Median 95 % CI




R Ratio of the mean T2 lesion count for a typical subject in higher baseline lesion activity
group to lower baseline lesion activity group
4.71 4.81 (3.48, 6.25)
l2 Baseline mean T2 lesion count for a typical subject in the higher baseline lesion activity
sub-population
0.031 0.031
r1 Dispersion parameter for baseline k in the lower baseline lesion activity sub-population 35.7 35.5 (30.6, 40.6)
r2 Dispersion parameter for baseline k in the higher baseline lesion activity sub-population 0.459 0.454 (0.396,
0.518)
h Proportion of subjects with lower baseline lesion activity 0.354 0.353 (0.315,
0.394)
b Slope of AUC effect on log(k) -0.0147 -0.0147 (-0.0170,
-0.0124)
r2 Variance of random effect on baseline k in log scale for the higher baseline lesion activity
sub-population
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1008060 120
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6
Fig. 6 Observed marginal mean new or newly enlarged T2 lesion
count by AUCss subgroup, overlaid with mean and 95 % CI based on
1000 simulations. Boxplot of the population PK model estimated
AUCss in the every-2-week and every-4-week arms. The simulation-
based mean curve is aligned with the central tendency of the observed
data. In addition, the observed mean lies within the simulation-based
95 % CI. Across the range of AUCss resulting from the every-2-week
regimen, marginal mean T2 lesion count had little change. However,
in the range of AUCss resulting from the every-4-week regimen, a
substantial difference in marginal mean T2 lesion count was either
observed in the data or predicted by the model
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captured the important features of the data, including an
excessive proportion of zero counts, over dispersion, pro-
portion of large counts greater than that implied by the
typical count models, and heterogeneity in within-subject
variation. This analysis suggested that SC peginterferon b-
1a exposure is significantly related to the reduction in
Gd? (and T2) lesion count over time, and that the
increased reduction in Gd? and new or newly enlarged
T2 lesion count with the every-2-week regimen compared
with the every-4-week regimen was related to the higher
exposure. The every-2-week regimen produced an expo-
sure range that is close to the plateau range of the
exposure–response curve, while the every-4-week regimen
could lead to a substantial proportion of subjects with
suboptimal exposure to SC peginterferon b-1a. Since the
safety profiles are similar among the two regimens, and
the every-2-week regimen provided superior efficacy, this
regimen was the one proposed to and recommended by
the FDA and EMA labels [22, 23].
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